Unraveling Cancer

Fixed vs. Continuous CLL Treatment Explained

In this episode of the Patient Power podcast, Unraveling Cancer, patient host Brad Adams is joined by Paul J. Hampel, MD, a hematologist-oncologist at Mayo Clinic in Rochester, for a conversation about fixed duration versus continuous treatment for chronic lymphocytic leukemia (CLL), including benefits, side effects, monitoring, and how to choose the best option based on your lifestyle and disease features.

New Immune Advances in CLL

In this episode of the Patient Power podcast, Unraveling Cancer, patient host Michele Nadeem-Baker is joined by Thomas Kipps, MD, PhD, UC San Diego, for a conversation about the latest immune-based advances in chronic lymphocytic leukemia (CLL), including targeted therapies, CAR T-cell treatment, vaccines, and infection prevention. Learn how new research is improving outcomes and bringing hope for a future cure.

Is Fixed Duration Therapy the New Standard?

Patient advocate, Michele Nadeem Baker, hosts Boyu Hu, MD, Director of Lymphoma and Chronic Lymphocytic Leukemia at the Huntsman Cancer Institute at the University of Utah for a discussion on fixed duration treatment.

From Diagnosis to Treatment End: Navigating Fixed-Duration Therapy for CLL

Physician assistant Jill Miller shares what CLL patients really need to know about fixed-duration treatment. Learn how to manage side effects, what to expect month by month, when treatment ends, and how to navigate the emotional transition from active therapy to surveillance.

Functional Cure? The Promise of CLL Combination Therapy

In this episode of Patient Power’s podcast Unraveling Cancer, patient host Michele Nadeem-Baker speaks with Daniel Ermann, MD, Huntsman Cancer Institute, about how combination therapies are revolutionizing treatment for chronic lymphocytic leukemia. Dr. Ermann shares updates from recent clinical trials, the growing reality of chemo-free treatment, and promising developments such as bispecific antibodies and CAR T-cell therapy. The conversation gives patients insight into the rapidly advancing world of CLL care and what’s on the horizon.